Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.
In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.
Company’s Keywords:
<5
<2500000
<
<2009
Your request has been submitted successfully.
Own or work here?